Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

Inflammation leads to atherosclerosis and acute coronary syndromes (ACS). We performed a prospective, observational study to assess association between the concentrations of inflammatory markers (high sensitivity C-reactive protein, hsCRP; high sensitivity interleukin6, hsIL-6; soluble CD40 ligand,...

Full description

Bibliographic Details
Main Authors: Benedikt S. Biesinger, Aleksandra Gasecka, Thomas Perkmann, Johann Wojta, Maciej Lesiak, Marek Grygier, Ceren Eyileten, Marek Postuła, Krzysztof J. Filipiak, Aurel Toma, Christian Hengstenberg, Jolanta M. Siller-Matula
Format: Article
Language:English
Published: Taylor & Francis Group 2021-05-01
Series:Platelets
Subjects:
acute coronary syndrome
inflammation
platelet reactivity
prasugrel
statin
ticagrelor
Online Access:http://dx.doi.org/10.1080/09537104.2020.1766670

Internet

http://dx.doi.org/10.1080/09537104.2020.1766670

Similar Items